Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2
Completed
The purpose of this noncomparative study is to obtain preliminary estimates of the efficacy of erlotinib and standard chemotherapy in patients with advanced, previously untreated nonsmall cell lung cancer (NSCLC) and an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 2. The study will also evaluate the safety of single-agent erlotinib in this patient population.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2012
Locations: Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
Conditions: Non-Small Cell Lung Cancer
Erlotinib (Tarceva) as a Single Agent or Intercalated With Combination Chemotherapy in Patients With EGFR Positive NSCLC
Completed
This will be the first prospective study where patients will be selected on the basis of two measures of the epidermal growth factor receptor (EGFR) pathway. The study will assess prospectively the efficacy of erlotinib as a single agent or intercalated with chemotherapy in highly selected patients with EGFR overexpression and/or EGFR amplification.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2012
Locations: Fox Chase Cancer Center, Philadelphia, Pennsylvania +1 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor
Completed
To determine the best dose of this investigational agent AG-013736 in combination with various standard of care treatments for advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/30/2012
Locations: Pfizer Investigational Site, Philadelphia, Pennsylvania
Conditions: Neoplasms
High-Dose Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Metastatic Breast Cancer
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of high-dose chemotherapy and peripheral stem cell transplantation in treating patients with recurrent or refractory metastatic breast cancer.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/19/2012
Locations: University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania +1 locations
Conditions: Breast Cancer
A Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Stage IIIb/IV NSCLC
Completed
The primary objective of this study will be to determine the progression free survival of patients with stage IIIb/IV non-small cell lung cancer (NSCLC) treated with dual agent monoclonal antibody therapy consisting of cetuximab and bevacizumab in combination with two different regimens of paclitaxel and carboplatin chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2011
Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Langhorne, Pennsylvania +2 locations
Conditions: Non-Small Cell Lung Cancer
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Brain Cancer
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation or bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combining temozolomide, thiotepa, and carboplatin followed by peripheral stem cell transplantation or bone marrow transplantation in treating patients who have brain c... Read More
Gender:
ALL
Ages:
Between 1 year and 49 years
Trial Updated:
03/25/2011
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Brain and Central Nervous System Tumors
Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer
Unknown
RATIONALE: Imaging procedures, such as fludeoxyglucose F18 positron emission tomography (\^18FDG-PET), may improve the ability to detect disease progression and help doctors predict a patient's response to treatment and plan more effective treatment. PURPOSE: This phase II trial is studying how well \^18FDG-PET imaging works in detecting disease progression and determining response to treatment in patients who are undergoing chemoradiotherapy for locally advanced non-small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/26/2011
Locations: Kimmel Cancer Center at Thomas Jefferson University - Philadelphia, Philadelphia, Pennsylvania +4 locations
Conditions: Lung Cancer
N99-01: Combination Chemotherapy, Radiation Therapy, and Stem Cell Transplantation in Treating Patients With Neuroblastoma
Completed
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Giving the drugs in different ways may kill more tumor cells. Radiation therapy uses high-energy x-rays to damage tumor cells. Peripheral stem cell or bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy. PURPOSE: This phase I trial is studying the side effects and best dose of combination chemotherapy whe... Read More
Gender:
ALL
Ages:
Between 1 year and 21 years
Trial Updated:
10/14/2010
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Neuroblastoma
Combination Chemotherapy Followed by Bone Marrow or Stem Cell Transplantation in Treating Patients With Relapsed or Refractory Germ Cell Tumors
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow doctors to give higher doses of chemotherapy and kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of combination chemotherapy followed by peripheral stem cell transplantation or bone marrow transplantation in treating patients who have relapsed or recurrent germ cell cancer.
Gender:
ALL
Ages:
Between 15 years and 60 years
Trial Updated:
09/30/2010
Locations: Temple University Cancer Center, Philadelphia, Pennsylvania
Conditions: Extragonadal Germ Cell Tumor, Ovarian Cancer, Testicular Germ Cell Tumor
High-Dose Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Poor-Prognosis Breast Cancer
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining peripheral stem cell transplantation with combinations of drugs may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of high-dose combination chemotherapy followed by peripheral stem cell transplantation or autologous bone marrow transplantation in women with stage II breast cancer with eight or more positive axillary lymph nodes and in wom... Read More
Gender:
FEMALE
Ages:
Between 15 years and 60 years
Trial Updated:
09/30/2010
Locations: Temple University Cancer Center, Philadelphia, Pennsylvania
Conditions: Breast Cancer
Carboplatin Plus Cetuximab for Treatment of Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)
Completed
This is a phase II study in previously untreated subjects with histologically or cytologically proven stage IIIB/IV NSCLC designed to determine the efficacy of first line treatment with carboplatin and cetuximab.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/08/2010
Locations: ImClone Investigational Site, Langhorne, Pennsylvania +1 locations
Conditions: Non-small Cell Lung Cancer
Trial of Carboplatin/Paclitaxel/Cetuximab in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)
Completed
The purpose of the study is to determine if the combination of cetuximab, carboplatin and paclitaxel will shrink a specific type of lung cancer known as non-small cell lung cancer (NSCLC). The safety of this combination will also be evaluated.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/08/2010
Locations: ImClone Investigational Site, Philadelphia, Pennsylvania
Conditions: Non-small Cell Lung Cancer